2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1470

Russell Bodies and Serological Status in Rheumatoid Arthritis
Abstract Number: 1471

ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients
Abstract Number: 1472

Preliminary Analysis of Genetic Variants in the Immune System Related to the Body Mass Index in Early Arthritis Patients
Abstract Number: 1473

Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Abstract Number: 1474

Circulating Transfer RNA-Derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Abstract Number: 1475

Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly
Abstract Number: 1476

Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis
Abstract Number: 1477

Serum Autoantibody Multi-Analyte Testing in Rheumatoid Arthritis Can Reduce Avoidable Costs Associated from False Positive Results. a Simulation Study in the United States of America
Abstract Number: 1478

Factors Associated with Disability and Health-Related Quality of Life in Biologic-Treated Patients with Rheumatoid Arthritis in Persistent Moderate Disease Activity
Abstract Number: 1479

The Predictive Utility of Anti-Cyclic Citrullinated Peptide Antibodies to Diagnose Rheumatoid Arthritis in Patients with Hepatitis C and Polyarthralgias
Abstract Number: 1480

Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
Abstract Number: 1481

Are ACPA Associated with More Bone Loss over Time in Patients with RA?
Abstract Number: 1482

Is 14.3.3η a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?
Abstract Number: 1483

Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Abstract Number: 1484

Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].